Recent Company News

• 09:35 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - China Healthcare March Recap

• 05:20 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:17 AM ET Apr 07, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:58 AM ET Apr 07, 2026
  

  Media, chemicals, food/beverage the top gainers; healthcare, tech and industrials the big laggards:

• 01:01 AM ET Apr 07, 2026
  

  Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP (€82.58, 0.00)

• 03:40 PM ET Apr 02, 2026
  

  White House announces tariffs on patented pharmaceuticals

• 01:08 AM ET Mar 31, 2026
  

  Sanofi's Rezurock receives EU conditional approval for Chronic Graft-Versus-Host disease treatment in adults and children aged 12 years (€81.90, 0.00)

• 02:54 AM ET Mar 30, 2026
  

  StreetAccount Summary - European pre-market trading update

• 11:03 AM ET Mar 28, 2026
  

  Sanofi announces new results from amlitelimab phase 3 studies in atopic dermatitis (€81.99, 0.00)

• 08:11 AM ET Mar 27, 2026
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Sanofi's Sarclisa (€82.43, +1.28)